BiotechTube

Panobinostat (LBH589)

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Graft-Versus-Host Disease

Conditions

Graft-Versus-Host Disease

Trial Timeline

Apr 1, 2010 → Jun 1, 2016

NCT ID
NCT01111526

About Panobinostat (LBH589)

Panobinostat (LBH589) is a phase 1/2 stage product being developed by Novartis for Graft-Versus-Host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01111526. Target conditions include Graft-Versus-Host Disease.

What happened to similar drugs?

0 of 6 similar drugs in Graft-Versus-Host Disease were approved

Approved (0) Terminated (0) Active (6)
🔄Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3
🔄INCA034176 + Best Available Therapy (BAT)IncytePhase 3
🔄INCA034176IncytePhase 3
🔄Itacitinib + Placebo + Prednisone + MethylprednisoloneIncytePhase 3
🔄INCA034176 + Placebo + CorticosteroidsIncytePhase 3
🔄Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + IbrutinibIncytePhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT00985946Phase 2Terminated
NCT01111526Phase 1/2Completed
NCT00997399Phase 1Completed
NCT00993642Phase 1Withdrawn
NCT01528501Phase 2Terminated
NCT00699296Phase 2Terminated

Competing Products

20 competing products in Graft-Versus-Host Disease

See all competitors
ProductCompanyStageHype Score
AlefaceptAstellas PharmaPhase 2
27
EQ001 + EQ001 PlaceboBioconPhase 1/2
32
SHR0302Jiangsu Hengrui MedicinePhase 1
29
Prednisone + Jakavi(ruxolitinib) + PrednisoneNovartisPhase 2
42
PredEverNovartisPhase 2
35
Lifitegrast 5% Ophthalmic Solution + PlaceboNovartisPhase 1
29
LBH589 + MethylprednisoloneNovartisPhase 2
27
FilgrastimAmgenPre-clinical
18
AMG 592AmgenPhase 1
29
AMG 592AmgenPhase 1
29
BMS-986004 + Sirolimus + TacrolimusBristol Myers SquibbPhase 1
29
Belumosudil (KD025)SanofiPhase 2
27
Belumosudil 200 mg QD + Belumosudil 200 mg BID + Belumosudil 400 mg QDSanofiPhase 2
35
AAT + PlaceboCSLPhase 2/3
42
Ruxolitinib + MethylprednisoloneIncytePhase 2
39
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3
44
Itacitinib + CorticosteroidsIncytePhase 1/2
21
RuxolitinibIncytePre-clinical
23
Itacitinib + CorticosteroidIncytePhase 1
26
INCA034176IncytePhase 1/2
36